Phathom Pharmaceuticals, Inc. Current Ratio

Current Ratio of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.


Highlights and Quick Summary

  • Current Ratio for the quarter ending September 29, 2021 was 8.1 (a 51.85% increase compared to previous quarter)
  • Year-over-year quarterly Current Ratio increased by 54.39%
  • Annual Current Ratio for 2020 was 5.25 (a -92.31% decrease from previous year)
  • Annual Current Ratio for 2019 was 68.2 (a 16444.54% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of Phathom Pharmaceuticals, Inc.

Most recent Current Ratioof PHAT including historical data for past 10 years.

Interactive Chart of Current Ratio of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 8.1 5.34 5.94
2020 5.25 8.21 18.76 57.22 5.25
2019 68.2 0.37 68.2
2018 0.41 0.41

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.